Literature DB >> 12745174

Characteristics of a medical care program for specific diseases in Japan in an era of changing cost-sharing.

Hiroki Nakatani1, Takefumi Kondo.   

Abstract

The Medical Care Program for Specific Diseases (Specific Diseases Program) was initiated in 1972. The Program has two major components; research grant for specific diseases and medical cost subsidy for specific diseases. The research grant component now targets 118 diseases, and the medical cost subsidy component supports all or part of the co-payments of medical expenses for patients of 44 out of the 118 research target diseases. The present study reviewed public assistance programs for the vulnerable population in Japan, particularly those with designated Specific Diseases, in the context of the wider social security system. Existing governmental information were abstracted and analyzed. The results showed that the recent reform of the Specific Disease Program, which requires the patients in this Program to share a small portion of the medical costs, influenced the number of patients and health services utilization. Other health insurance reforms also have significant effects on the number of patients registered in the Specific Diseases Program, reflecting the relative merit/demerit of the Program in comparison with the general health insurance scheme. Therefore, in an environment of social security reform, formulation of health care policies for specific programs should take into account the relative merits and demerits of the Program in question, in comparison with the general health insurance scheme, to avoid misestimating the number of patients covered by the Program and their utilization of health care services.

Entities:  

Mesh:

Year:  2003        PMID: 12745174     DOI: 10.1016/s0168-8510(02)00199-9

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  3 in total

1.  Effect of plasma exchange on in-hospital mortality in patients with pulmonary hemorrhage secondary to antineutrophil cytoplasmic antibody-associated vasculitis: A propensity-matched analysis using a nationwide administrative database.

Authors:  Eishi Uechi; Masato Okada; Kiyohide Fushimi
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

2.  Changes in the Penetration Rate of Biosimilar Infliximab Within Japan Using a Japanese Claims Database.

Authors:  Tsugumi Matsumoto; Takanori Tsuchiya; Takahiro Hirano; Thomas Laurent; Kazuhisa Matsunaga; Jiro Takata
Journal:  Clinicoecon Outcomes Res       Date:  2021-02-25

3.  National Registry of Designated Intractable Diseases in Japan: Present Status and Future Prospects.

Authors:  Yasuhiro Kanatani; Naoko Tomita; Yoko Sato; Akiko Eto; Hiroe Omoe; Hiroshi Mizushima
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-09-21       Impact factor: 1.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.